The objective of this study is to assess the effectiveness of Clevudine once daily dosing in viral suppression of Hepatitis B Virus DNA level compared to placebo and/or nucleoside/nucleotide analogues. Other parameters such as reducing ALT levels, HBeAg seroconversion and adverse events observed in Clevudine compared to placebo and/or nucleoside/nucleotide analogues were also analyzed.